Background:  Proprotein convertase subtilisin/kexin type 1 inhibitor, PCSK1N is proposed be a specific endogenous inhibitor of PCSK1 and may function in the control of the neuroendocrine secretory pathway. It interacts via the C-terminal inhibitory domain with PCSK1 66 kDa form to reduce PCSK1 activity in the endoplasmic reticulum and Golgi, and slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. PCSK1N may control the intracellular timing of PCSK1 rather than its total level of activity.

Description: Rabbit polyclonal to SAAS

Immunogen: KLH conjugated synthetic peptide derived from SAAS

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 27 kDa;

·Immunohistochemistry (Frozen/paraffin tissue section): 1/50-200;

·Immunocytochemistry: 1/100;

· Optimal working dilutions must be determined by the end user.